SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease affecting some women with tuberous sclerosis complex (TSC). Sporadic LAM can develop in women without TSC, owing to somatic mutations in the TSC2 gene. Accumulating evidence supports the view of LAM as a low-grade, destructive, metastasizing neoplasm. The mechanisms underlying the metastatic capability of LAM cells remain poorly understood. The observed behavior of LAM cells with respect to their infiltrative growth pattern, metastatic potential, and altered cell differentiation bears similarity to cells undergoing epithelial-mesenchymal transition. Here, we report increased levels of active Src kinase in LAM lungs and in TSC2(-/-) cells, caused by a reduction of autophagy. Furthermore, increased Src kinase activation promoted migration, invasion, and inhibition of E-cadherin expression in TSC2(-/-) cells by upregulating the transcription factor Snail. Notably, Src kinase inhibitors reduced migration and invasion properties of TSC2(-/-) cells and attenuated lung colonization of intravenously injected TSC2(-/-) cells in vivo to a greater extent than control TSC2(+/+) cells. Our results reveal mechanistic basis for the pathogenicity of LAM cells and they rationalize Src kinase as a novel therapeutic target for treatment of LAM and TSC.

[1]  W. Travis,et al.  Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. , 2012, American journal of respiratory and critical care medicine.

[2]  E. Henske,et al.  Lymphangioleiomyomatosis - a wolf in sheep's clothing. , 2012, The Journal of clinical investigation.

[3]  Owen J. Sansom,et al.  Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling , 2011, Nature Cell Biology.

[4]  Chau Dang,et al.  Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. , 2011, Clinical breast cancer.

[5]  D. Kwiatkowski,et al.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent , 2011, Proceedings of the National Academy of Sciences.

[6]  J. Krischer,et al.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[7]  R. Yeung,et al.  Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition. , 2010, The American journal of pathology.

[8]  Christopher Logothetis,et al.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.

[9]  Kathryn G. Foster,et al.  Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony* , 2010, The Journal of Biological Chemistry.

[10]  W. Bailey,et al.  An official American Thoracic Society workshop report: tobacco control initiatives within the American Thoracic Society. , 2010, Proceedings of the American Thoracic Society.

[11]  E. Henske,et al.  Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. , 2010, Proceedings of the American Thoracic Society.

[12]  R. Jensen,et al.  Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. , 2010, American journal of respiratory cell and molecular biology.

[13]  E. Goncharova,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Abnormal Proliferation and Survival of TSC2-Deficient Cells: Relevance to Pulmonary Lymphangioleiomyomatosis , 2009, Molecular Pharmacology.

[14]  Zhon-Yin Zhang,et al.  PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. , 2009, Biochemistry.

[15]  G. Giaccone,et al.  Src as a potential therapeutic target in non-small-cell lung cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[17]  F. Elmslie,et al.  Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[18]  Masaaki Komatsu,et al.  Homeostatic Levels of p62 Control Cytoplasmic Inclusion Body Formation in Autophagy-Deficient Mice , 2007, Cell.

[19]  G. Sethuraman,et al.  Rapamycin causes regression of astrocytomas in tuberous sclerosis complex , 2006, Annals of neurology.

[20]  D. Noonan,et al.  Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2. , 2006, American journal of respiratory cell and molecular biology.

[21]  J. Moss,et al.  Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[23]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[24]  R. Yeung.  Multiple roles of the tuberous sclerosis complex genes , 2003, Genes, chromosomes & cancer.

[25]  D. Kwiatkowski,et al.  Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation , 2002, The Journal of Biological Chemistry.

[26]  D. Kwiatkowski,et al.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. , 2001, American journal of respiratory and critical care medicine.

[27]  T. Hartman,et al.  High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. , 2000, Mayo Clinic proceedings.

[28]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Travis,et al.  Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. , 2000, Archives of pathology & laboratory medicine.

[30]  V. Ferrans,et al.  Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. , 1999, American journal of respiratory cell and molecular biology.

[31]  R. Yeung,et al.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S Povey,et al.  The genetic basis of tuberous sclerosis. , 1998, Molecular medicine today.

[33]  L. Liotta,et al.  Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). , 1997, Human pathology.

[34]  T. Hunter,et al.  Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.

[35]  J. Parsons,et al.  Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src , 1994, Molecular and cellular biology.

[36]  J. Brugge,et al.  Analysis of mutant forms of the c-src gene product containing a phenylalanine substitution for tyrosine 416. , 1990, Oncogene research.